Targeting ferroptosis: a new therapeutic opportunity for kidney diseases
Clin Pharmacol Ther 88:394399
Aardvark Therapeutics Sector: Oral gut-restricted bitter taste receptor agonists for hunger suppression HQ: San Diego, CA Year Founded: 2017 Origin Story: Aardvark Therapeutics was founded around a mechanistically distinct hypothesis: rather than suppressing appetite like GLP-1 drugs, the companys lead compound activates bitter taste receptors (TAS2Rs) confined to the gastrointestinal tract to trigger local release of satiety hormones, targeting hunger itself without systemic drug exposure
The ratio of reduced GSH to the disulfide form (GSH/GSSG) within the endoplasmic reticulum ranges from 1:1 to 4:1, whereas the overall cellular GSH/GSSG ratio ranges from 30:1 to 100:1 (26) (Figure 2)
16 Figure 3: Risk of OACs in patients on GLP-1s versus patients on insulin Conclusion GLP-1s, initially developed to help manage and treat diabetes and later used to treat obesity, are now showing significant potential to help prevent and treat CVD, mental health disorders, liver and kidney disorders, neurodegenerative disorders, addiction disorders, and cancer
Rare But Possible Side Effects Although uncommon, there are rare side effects to be aware of
